CLAIMS

1. A therapeutic agent that activates mTORC1 function and/or increases Ras Homolog Enriched in Striatum (Rhes) level in a subject's brain for use in the treatment or prevention of Huntington's disease (HD).

2. Use of a therapeutic agent that activates mTORC1 function and/or increases Ras Homolog Enriched in Striatum (Rhes) level in a subject's brain in the manufacture of a medicament for the treatment or prevention of Huntington's disease (HD).

3. The therapeutic agent according to claim 1 or the use of the therapeutic agent according to claim 2, wherein the subject may have mitochondrial dysfunction, aberrant cholesterol homeostasis, striatal atrophy, impaired dopamine signaling and/or decreased autophagy.

4. A therapeutic agent that activates mTORC1function and/or increases Ras Homolog Enriched in Striatum (Rhes) level in a subject's brain for use in the modulation of mHTT-associated metabolic phenotypes and/or reversal of striatal atrophy.

5. Use of a therapeutic agent that activates mTORC1function and/or increases Ras Homolog Enriched in Striatum (Rhes) level in a subject's brain in the manufacture of a medicament for the modulation of mHTT-associated metabolic phenotypes and/or reversal of striatal atrophy

6. The therapeutic agent according to claim 1, 3 or 4, or the use of the therapeutic agent according to claim 2, 3 or 5, wherein the therapeutic agent comprises an mTORC1 regulator.

7. The therapeutic agent or the use of the therapeutic agent according to claim 6, wherein the mTORC1 regulator is Rheb.

8. The therapeutic agent or the use of the therapeutic agent according to claim 7, wherein the Rheb is constitutively active Rheb mutant (caRheb; S16H).

9. The therapeutic agent or the use of the therapeutic agent according to claim 8, wherein the therapeutic agent is contained in a viral vector.

10. The therapeutic agent or the use of the therapeutic agent according to claim 9, wherein the viral vector is an adeno-associated viral (AAV) vector.

11. The therapeutic agent according to claim 1, 3 or 4, or the use of the therapeutic agent according to claim 2, 3 or 5, wherein the therapeutic agent comprises Rhes.

12. The therapeutic agent or the use of the therapeutic agent according to claim 11, wherein the therapeutic agent is contained in a viral vector.

13. The therapeutic agent or the use of the therapeutic agent according to claim 12, wherein the viral vector is an adeno-associated viral (AAV) vector.

14. The therapeutic agent or the use of the therapeutic agent according to claim 13, wherein the AAV is AAV1, AAV2, AAV5, AAV6 and/or AAV9.

15. The therapeutic agent or the use of the therapeutic agent according to claim 14, wherein the AAV is AAV2.

16. The therapeutic agent or the use of the therapeutic agent according to claim 14, wherein the AAV is AAV2/1.

17. The therapeutic agent according to any one of claims 1, 3-4 and 6-16, or the use of the therapeutic agent according to any one of claims 2-3, 5 and 6-16, wherein the therapeutic agent is to be administered to the brain of the subject either directly or via the bloodstream.

18. The therapeutic agent or the use of the therapeutic agent according to claim 17, wherein the therapeutic agent is to be administered to the subject's striatum, cortex or ventricular space.

19. The therapeutic agent according to any one of claims 1, 3-4 and 6-18, or the use of the therapeutic agent according to any one of claims 2-3, 5 and 6-18, wherein the subject is human.

20. The therapeutic agent according to any one of claims 1, 3-4 and 6-19, or the use of the therapeutic agent according to any one of claims 2-3, 5 and 6-19, wherein the agent is to be injected at 1-5 locations in the CNS.

21. The therapeutic agent or the use of the therapeutic agent according to claim 20, wherein the agent is to be injected at a single location in the brain.